Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today reported its financial results for the first quarter ended March 31, 2014.
“During the first quarter, Genocea continued to make important strides toward our goal of developing and commercializing life-changing T cell-enabled medicines,” said Chip Clark, president and chief executive officer of Genocea.
Help employers find you! Check out all the jobs and post your resume.
